Compare IDEXX Laboratories, Inc. (IDXX) vs L3Harris Technologies Inc (LHX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs L3Harris Technologies Inc — how do they compare? IDEXX Laboratories, Inc. trades at $563.81 (market cap $44.48B), while L3Harris Technologies Inc trades at $277.71 (market cap $52.27B). The key difference: L3Harris Technologies Inc is the larger of the two by market cap, and L3Harris Technologies Inc pays a 1.78% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | LHX | |
|---|---|---|
Market Cap | $44.48B | $52.27B |
Sector | Health | Industrials |
52-Week High | $766.68 | $378.48 |
52-Week Low | $520.87 | $263.09 |
Enterprise Value | $45.38B | $63.03B |
Dividend Yield | — | 1.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories trades at $552.46, down 2.64% today, with neutral technical signals but strong fundamental performance. The company maintains robust profitability with 24.63% net margins and has beaten earnings expectations for three consecutive quarters. Recent news highlights AI integration in medical devices and upcoming Q2 2026 results on August 4, 2026. The stock shows consistent revenue growth from $3.4B in 2022 to $4.3B in 2025.
Outlook remains positive given earnings momentum and analyst consensus, though elevated valuation ratios (P/E 41.49) pose risks. Key catalysts include Q2 earnings release and continued AI adoption in veterinary diagnostics. Primary risks involve competitive pressures and market volatility affecting premium valuations.
LHX trades at $277.71, down 1.52% on the day, with a bearish technical signal but strong fundamental performance. The company has beaten earnings estimates for three consecutive quarters, with Q1 2026 EPS of $2.72 exceeding the $2.53 expectation. Recent contract wins, including a U.S. Space Force satellite award and U.S. Army communication system orders, highlight ongoing defense sector strength. The stock's valuation includes a P/E of 30.46 and a net income margin of 7.71% for 2025.
The outlook for LHX is positive, supported by a robust $40.7 billion backlog and 75% analyst buy ratings with a $367.50 consensus price target, implying significant upside. Key risks include execution on major contracts, defense budget fluctuations, and competitive pressures. The recent dividend of $1.25 per share underscores financial health, but investors should monitor debt levels and geopolitical factors affecting defense spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About L3Harris Technologies Inc
L3Harris Technologies was created in 2019 from the merger of L3 Technologies and Harris, two defense contractors that provide products for the command, control, communications, computers, intelligence, surveillance, and reconnaissance (C4ISR) market. The firm also has smaller operations serving the civil government, particularly the Federal Aviation Administration's communication infrastructure, and produces various avionics for defense and commercial aviation.
Read more on LHX →
